Strs Ohio Mirati Therapeutics, Inc. Transaction History

Strs Ohio

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Jan 24, 2022	SELL	$132.01 - $190.29 $1.19 Million - $1.71 Million	-9,000 Closed	0 $0
Q3 2021 Oct 22, 2021	SELL	$132.13 - $177.45 $792,780 - $1.06 Million	-6,000 Reduced 40.0%	9,000 $1.59 Million
Q2 2021 Jul 26, 2021	SELL	$144.0 - $179.73 $1.61 Million - $2.01 Million	-11,200 Reduced 42.75%	15,000 $2.42 Million
Q1 2021 Apr 23, 2021	BUY	$158.92 - $221.61 $2.4 Million - $3.35 Million	15,100 Added 136.04%	26,200 $4.49 Million
Q4 2020 Jan 25, 2021	BUY	$162.05 - $240.27 $777,840 - $1.15 Million	4,800 Added 76.19%	11,100 $2.44 Million

Q3 2020 Dec 14, 2020	BUY	$113.26 - $167.27 $90,608 - $133,816	800 Added 14.55%	6,300 $1.05 Million
Q2 2020 Jul 23, 2020	BUY	$72.01 - $120.39 $201,628 - $337,092	2,800 Added 103.7%	5,500 $627,000
Q1 2020 Apr 23, 2020	BUY	$69.78 - $116.21 $20,934 - $34,863	300 Added 12.5%	2,700 $207,000
Q4 2019 Jan 24, 2020	BUY	$70.76 - $128.86 $63,684 - $115,974	900 Added 60.0%	2,400 $309,000
Q2 2019 Jul 25, 2019	BUY	$59.49 - $104.71 $89,235 - $157,065	1,500 New	1,500 $154,000

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Strs Ohio, based on Form 13F filings with the SEC.

Stay updated on Strs Ohio with notifications on news.